Multiplex Imaging Mass Cytometry Reveals Prognostic Immunosuppressive Subpopulations and Macrophage-Driven Metastasis

Benjamin B Gyau1,2, Junyan Wang1,2, Weiguo Wu3

  • 1Section of Hematology and Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA.

Cancers
|September 13, 2025
PubMed

Insights

Metastasis in osteosarcoma is driven by M2 macrophages and immunosuppressive cells within the tumor microenvironment (TME). Targeting M2 macrophage signaling, like MIP-1α, may improve outcomes for osteosarcoma patients.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Metastasis is a primary cause of mortality in osteosarcoma (OS).
  • The immunosuppressive tumor microenvironment (TME) limits immunotherapy efficacy in OS.
  • Understanding TME composition is crucial for developing novel OS therapies.

Purpose of the Study:

  • To comprehensively map the immune and stromal cell populations in the OS TME.
  • To investigate the prognostic significance of TME cell abundance and spatial interactions.
  • To explore the role of macrophages in OS metastasis and identify potential therapeutic targets.

Main Methods:

  • Multiplex imaging mass cytometry and phenoplexing on 51 primary OS tumors.
  • Kaplan-Meier and Cox regression analyses for prognostic significance.
  • Orthotopic xenograft mouse models and in vitro assays to study macrophage function and metastasis.

Main Results:

  • Macrophages, particularly M2 subtypes, dominated the OS TME.
  • Increased M2 macrophages and myeloid-derived suppressor cells (MDSC) correlated with reduced metastasis-free survival.
  • Close spatial proximity of M2 macrophages with immunosuppressive cells formed pro-tumor hubs.
  • M2-derived MIP-1α (CCL3) was identified as a key chemokine promoting OS metastasis in vivo.

Conclusions:

  • The OS TME is characterized by a significant presence of M2 macrophages and MDSC.
  • Interactions between M2 macrophages and immunosuppressive cells are critical prognostic indicators for OS metastasis.
  • Targeting M2 macrophage-driven signaling pathways, such as MIP-1α, offers a promising strategy for novel osteosarcoma immunotherapies.

Related Concept Videos